TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: C-Cog in Early Course Schizophrenia Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults~2. Diagnosis of schizophrenia~3. Current Hospitalization or outpatient relapse~4. Fewer than four previous admissions~5. Willing to accept long-acting injectable treatment and participate in rehabilitation~Exclusion Criteria:~1. Primary diagnosis other than schizophrenia~2. Prior Long Acting Injectable treatment~3. Current Suicide Risk~4. Hypersensitivity to Aripiprazole~5. Pregnancy~6. Positive illicit drug screen other than cannabis (rescreening allowed in 4 weeks for drug positive cases)~7. Unable to give personal informed consent~8. History of treatment resistance as evidenced by clozapine treatment~9. Unable to stop treatment with medications that are strong Cytochrome (CYP) 2D6 or CYP 3A4 inhibitors and or strong CYP3A4 inducers (2.3, 7.1) for at 14 days prior to initiation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aripiprazole and Computerized Cognitive and Functional Skills Training Group (Type: EXPERIMENTAL): Participants in this arm will receive long-acting injectable aripiprazole every 2 months formulation for 12 consecutive months. Participants in this arm will also receive Computerized cognitive and functional skills training during the first 12 weeks of study participation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* pancreatic cancer, surgically unresectable or with metastases;~* no previous chemotherapy (except concomitant with radiotherapy);~* ECOG 0-2.~Exclusion Criteria:~* pancreatic cancer without histologic or cytologic confirmation;~* surgical resection possible;~* previous chemotherapy not concomitant with radiotherapy;~* ECOG 3-4.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Validation of Thermal Imaging to Detect Pneumonia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients 28-days to 17-years of age~* respiratory distress~* receive a chest x-ray~Exclusion Criteria:~* known chronic lung disease

- Gender: ALL
- Minimum Age: 28 Days
- Maximum Age: 17 Years
- Healthy Volunteers: None

Study Arms:
- Respiratory distress (Type: None): Inclusion criteria are 1) subjects 28-days to 17-years of age, 2) who have respiratory distress, and 3) who receive a chest x-ray. We will exclude subjects with known chronic lung disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Influence of an Acidic Beverage on the Imatinib Exposure After Major Gastrectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients ≥ 18 years of age~* Patients with GIST, who previously underwent major gastrectomy~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1~* Already selected to receive imatinib therapy in a dose of 400-800mg imatinib daily, as judged by the treating physician and with respect for and in agreement with the registration guidelines~* Subject is able and willing to sign the Informed Consent Form prior to screening~Exclusion Criteria:~* Concomitant administration of any anti-cancer therapies (e.g. chemo-therapy, other targeted therapy, experimental drug, etc) other than imatinib~* Concomitant use of medication which strongly inhibits or induces CYP3A4~* Refractory nausea and vomiting, malabsorption with other causes than gastrectomy or external biliary shunt that would preclude adequate absorption.~* Unwillingness to use Coca-Cola~* Unwillingness or inability to swallow whole tablets~* Inability to comply with the requirements of the protocol~* Inability to understand the nature and extent of the study and the procedures required~* Participation in a drug study within 60 days prior to the first day of this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- water (Type: NO_INTERVENTION): imatinib intake with water
- cola (Type: ACTIVE_COMPARATOR): imatinib intake with cola

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Percocet vs. Bupivicaine for Toothaches in the ED

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who present to the ED with a chief complaint of toothache, and a pain intensity rating of at least a 7 on an 11 item verbal numeric scale (from 0 or no pain to 10 or worst imaginable pain) will be eligible for enrollment.~* Patient should have the capacity to provide informed consent.~Exclusion Criteria:~* Patients presenting with a toothache due to trauma or post-operative procedure will be excluded as well as those requiring drainage of a dental abscess.~* Patients who have any contraindications to the medications used in the study (allergy, history of GI bleeding, etc.).~* Patients who cannot remain in the ED for at least 1 hour after study drug administration or do not have a ride home (if receiving Percocet) will be excluded from the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oral analgesic (Type: ACTIVE_COMPARATOR): 2 tablets of acetaminophen 325 mg/ oxycodone 5 mg orally once
- Injectable local anesthetic (Type: EXPERIMENTAL): local injection or nerve block with bupivicaine 0.5%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Movement and Fitness Trackers in Determining Performance Status

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of cancer.~* Undergoing screening for a University of Southern California (USC)/Norris therapeutic clinical trial operated by the Early and Developmental Therapeutics Program which includes both phase I and II clinical trials.~* Owns a smartphone.~* Ability to understand and the willingness to sign a written informed consent.~* Willingness to wear sensors to track physical activity, Global Positioning System (GPS) location, and provide symptom ratings each night during the screening period of their clinical trial and 180 days after starting treatments.~* Able to read English, Spanish, or traditional Chinese to complete patient reported outcomes.~* Able to ambulate without an assistive device.~Exclusion Criteria:~* Missing lower limbs.~* Symptomatic brain metastases are excluded from this clinical trial. However, those with asymptomatic brain metastasis are permitted. It is permissible to have the patient on corticosteroids to eliminate symptoms of brain metastasis.~* Known movement disorder such as Parkinson?s disease, choreoathetoid movement disorders, essential tremor if that movement disorder is of sufficient severity to require drug therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prevention (Fitbit, PRO diary) (Type: EXPERIMENTAL): Patients participant in movement assessment during 2 clinical trial visits. Patients also wear a Fitbit to track movements and complete a smartphone based PRO diary over 5-10 minutes to measure physical function, fatigue, sleep disturbance, social isolation, appetite, and body weight for up to 180 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Must be willing and able to provide fecal samples according to protocol schedule~* COHORT A~* Diagnosis of metastatic colorectal cancer, where the metastatic disease has not been previously treated~* Scheduled to begin fluorouracil/leucovorin calcium/oxaliplatin (FOLFOX) or folinic acid-fluorouracil-irinotecan (FOLFIRI) based chemotherapy for the advanced disease~* Must have radiologic evidence of disease~* COHORT B~* Diagnosis of metastatic cancer~* Scheduled to begin pembrolizumab or another anti-PD-1 or anti-PD-L1 antibody as single agent therapy for the treatment of the advanced disease~* Must have physical or radiologic evidence of disease~Exclusion Criteria:~* Patients with a colostomy or any other issues that may prevent the standard methods for collection of stool are not eligible for this study~* Patients are not enrolled or a research protocol for treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ancillary-Correlative (gut microbiome analysis) (Type: None): Patients undergo collection of fecal specimens at baseline, prior to start of each course of chemotherapy or immunotherapy, at the end of weeks 2, 4, 6, and 8, at the end of course 3 and courses thereafter of chemotherapy or immunotherapy, and at the time of disease progression or going off-treatment. Fecal specimens are analyzed via 16S ribosomal RNA gene sequencing, meta-transcriptomics analysis, and meta-proteomics analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Antibody Mediated Kidney Graft Rejection (ABMR)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Recipients of a renal allograft, male and female patients age \>18~* The eGF\>20 ml/min/1.73 m2,~* Renal biopsy Criteria: chronic active ABMR.~* Written informed consent, compliant with local regulations.~Exclusion Criteria:~* Recipients of multiple organs.~* Pregnant women.~* Malignant disease in last 5 years~* Active autoimmune disease~* Active infection including hepatitis B, hepatitis C, HIV, or tuberculosis~* Evidence of congestive cardiac failure and/or acute coronary syndrome in past 6 months.~* Evidence of liver disease~* Inadequate compliance to treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Historic control (Type: NO_INTERVENTION): historic cohort of patients with ABMR treated with standard of care therapy
- MSC transplantation (Type: EXPERIMENTAL): patients with ABMR treated with MSC transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women ≥18 years of age.~* Confirmed diagnosis of MBC (stage IV).~* Breast adenocarcinoma confirmed histologically.~* HER2-negative according to the American Society of Clinical Oncology (ASCO) and Anatomical Pathology (CAP) criteria for the detection of HER2 in breast cancer.~* Patients who have started treatment with nab-paclitaxel monotherapy no further than the third line of chemotherapy for metastatic disease in HER2-negative breast cancer during the period 2012-2014 (3 years) and who have received at least one cycle of treatment.~* Ability to give informed consent, preferably in writing or orally in front of a witness, before the start of data collection (if it is able to be given).~Exclusion Criteria:~* Patients with any medical or psychological disorder which in the investigator's opinion might compromise the ability of the patient to give their informed consent.~* Patients who have received treatment with nab-paclitaxel combined with other chemotherapy agents or anti-angiogenic drugs or tumor-targeting drugs with anti-tumor activity.~* Patients who have taken part in any clinical trial (interventional) during the study period.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abraxane® treatment in patients with metastatic breast cancer (Type: None): Patients diagnosed with HER2-negative MBC who have started treatment with nab-paclitaxel monotherapy no further than the third line of chemotherapy for metastatic disease during the past 3 years (2012-2014) and who give their consent to data collection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Trial of Stereotactic Radiation Therapy (SRT) Versus SRT Plus Vertebral Augmentation Procedure (VAP) for Vertebral Metastasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years.~2. ECOG performance status 0-1.~3. Known histologically proven malignancy.~4. Localized osteolytic spine metastases from T7 to L5 demonstrated by MRI, CT, PET or bone scan: a solitary spine metastasis; two separate spine levels; or up to 3 separate sites (each site may have a maximal involvement of 2 contiguous vertebral bodies with or without a paraspinal mass of no more than 5 cm).~5. Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential.~6. Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control.~7. Numerical Rating Pain Scale (NRPS) and movement-related pain score(MRPS) within two (2) weeks prior to registration.~8. The patient must have a score of ≥ 5 for at least one of the planned sites for SRT.~9. Patients must provide study specific informed consent prior to study entry.~10. Required Pre-treatment Evaluations: baseline Numerical Rating Pain Scale (NRPS), movement-related pain score, dose and frequency of all pain medications; QOL Measure using the Oswestry Disability Questionnaire, and EuroQOL(EQ-5D).~Exclusion Criteria:~1. Non-ambulatory patients.~2. Frank spinal cord compression or epidural compression within 3 mm of the spinal cord.~3. Osteoblastic vertebral metastasis.~4. Prior radiation to the index spine.~5. Patients with rapid neurologic decline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: ACTIVE_COMPARATOR): Baseline Assessments and followup assessments are the same for both arms. Control group Intervention: Stereotactic Radiation Therapy only
- Treatment Group (Type: EXPERIMENTAL): SRT with Vertebral Augmentation Procedure Baseline Assessments and followup assessments are the same for both arms. Treatment group Intervention: Stereotactic Radiation Therapy with Vertebral Augmentation Procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Acthar Gel in an Outpatient Dialysis Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion criteria will be individuals requiring dialysis for treatment of ESRD who have had poor response to immunosuppressive strategies.~* Non-Diabetic~* Adults age 18-80~Exclusion Criteria:~* receiving hemodialysis for \> 5 years~* diabetic, less than 18 years of age~* are pregnant~* have a history of cancer in the last 5 years~* have an active infection~* have recently had a myocardial infarction (within 6 weeks)~* have malignant arrhythmias, unstable angina, uncontrolled hypertension (SBP\> 180 and/or DBP \> 105)~* recent hospitalization (\< 30 days),~* ocular disease,~* accelerated osteoporosis,~* gastrointestinal diseases (ulcerative colitis, diverticulitis, myasthenia gravis)~* any disorder that may be exacerbated by short periods of activity.~* cognitive dysfunction~* neurological deficits leading to limited ambulation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 80 Units of Acthar (Type: ACTIVE_COMPARATOR): Subjects assigned by random assignment to receive 80 Units of Acthar Gel 2x weekly for 6 months
- 40 Units of Acthar (Type: ACTIVE_COMPARATOR): Subjects assigned by random assignment to receive 40 Units of Acthar Gel 2x weekly for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Pharmacodynamics of Pentobarbital in Neonates, Infants, and Children Following Open Heart Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Will receive intravenous pentobarbital for procedural/imaging sedation as standard of care~* Age(Neonates, Young Infants, Older Infants, and Children Up to 6 years old)~* Diagnosis either postop from cardiac surgery or requrie sedation with IV pentobarbital as standard of care~* Adequate liver function tests~* Informed consent~Exclusion Criteria:~* Pregnant or lactating females~* Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of stage I or II non-small cell lung cancer with complete resection of all disease~  * Must be free of recurrent or progressive disease~* Current smoker defined as:~  * Smoked at least 100 cigarettes in entire life AND~ * Currently smoking some days or every day~* Must establish a quit date that falls within 30 days after registration, but 7 days after physician advice and start of bupropion or placebo therapy~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Zubrod 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Not specified~Renal:~* Not specified~Cardiovascular:~* Not within an immediate post-infarction period~* No uncontrolled arrhythmias~* No unstable angina~* No uncontrolled hypertension (unstable blood pressure, diastolic pressure 90 mm Hg or greater)~Other:~* Must be able to read, speak, and understand English~* Must be willing to allow testing of saliva for cotinine levels~* No history of seizures~* No history of eating disorders~* No known drug-drug interactions between nicotine patch and/or bupropion and patient's current or planned medications including chemotherapy and antiemetics~* No concurrent psychiatric diagnosis that would preclude study compliance~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Concurrent adjuvant chemotherapy allowed~Endocrine therapy:~* No concurrent systemic steroids~Radiotherapy:~* Concurrent adjuvant radiotherapy allowed~Surgery:~* See Disease Characteristics~* Recovered from prior surgery~Other:~* Prior neoadjuvant therapy allowed~* At least 14 days since prior medications containing bupropion (e.g., Wellbutrin or Wellbutrin SR)~* No other concurrent medications that contain bupropion (e.g., Wellbutrin or Wellbutrin SR)~* No concurrent monoamine oxidase inhibitors~* No concurrent medications that lower seizure threshold (e.g., antipsychotics, antidepressants, or theophylline)~* No other concurrent nicotine replacement therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Behavioral Intervention + Placebo (Type: PLACEBO_COMPARATOR): Smoking cessation intervention , nicotine replacement, psychosocial assessment and care, and placebo.
- Behavioral Intervention + Bupropion (Type: ACTIVE_COMPARATOR): Smoking cessation intervention, nicotine replacement, psychosocial assessment and care, and bupropion hydrochloride .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues